Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

QBREXZA 2.4% CLOTH

glycopyrronium
$20.5973per EA

Strength

2.4 g/100g

Manufacturer

Journey Medical Corporation

NDC

69489041130

Classification

Brand

Dosage Form

CLOTH

Route

TOPICAL

Last Updated

2/22/2023

Active Ingredients

GLYCOPYRRONIUM TOSYLATE

Approval Type

New Drug (NDA)

FDA Application

NDA210361

On Market Since

6/28/2018

Pharmacological Classes

Anticholinergic
Cholinergic Antagonists
Cholinergic Muscarinic Antagonist
Cholinergic Muscarinic Antagonists

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

0.0%

1Y

0.0%

3Y

0.0%

5Y

N/A

All

+6.6%

Generic Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.

Related Drugs

Same classification

CUVPOSA 1 MG/5 ML SOLUTION
Brand
00259050116•Merz Pharmaceuticals, LLC
$1.0081
per ML
VESICARE LS 5 MG/5 ML SUSP
Brand
51248025099•Astellas Pharma US, Inc.
$1.6383
per ML
OXYTROL FOR WOMEN 3.9 MG/24HR
Brand
00023963704•Allergan, Inc.
$2.7368
per EA
OXYTROL FOR WOMEN 3.9 MG/24HR
Brand
00023963708•Allergan, Inc.
$2.7368
per EA
LOMOTIL 2.5-0.025 MG TABLET
Brand
00025006131•Pfizer Inc.
$3.0028
per EA
MOTOFEN 1-0.025 MG TABLET
Brand
54766020010•Sebela Pharmaceuticals Inc.
$6.9129
per EA
ANORO ELLIPTA 62.5-25 MCG INH
Brand
00173086910•GlaxoSmithKline LLC
$7.8122
per EA
ANORO ELLIPTA 62.5-25 MCG INH
Brand
00173086906•GlaxoSmithKline LLC
$8.0331
per EA
INCRUSE ELLIPTA 62.5 MCG INH
Brand
00173087306•GlaxoSmithKline LLC
$10.2684
per EA
SPIRIVA HANDIHALER 18 MCG CAP
Brand
00597007547•Boehringer Ingelheim Pharmaceuticals Inc.
$10.6188
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy